Screening of methylenedioxyamphetamine- and piperazine-derived designer drugs in urine by LC-MS/MS using neutral loss and precursor ion scan

Journal of Mass Spectrometry

Volumn 48, Issue 1, 2013, Pages 49-59

  Montesano, Camilla ^a   Sergi, Manuel ^b   Moro, Mariaelena ^a   Napoletano, Sabino ^a,c   Romolo, Francesco Saverio ^a,d   Carlo, Michele Del ^b   Compagnone, Dario ^b   Curini, Roberta ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c MINISTRY OF THE INTERIOR   (Italy)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

designer drugs; LC MS MS; methylenedioxyamphetamine; neutral loss scan; piperazine derived; precursor ion scan

Indexed keywords

DESIGNER DRUGS; LC-MS/MS; METHYLENEDIOXYAMPHETAMINE; NEUTRAL LOSS; PIPERAZINE-DERIVED; PRECURSOR-ION SCAN;

BODY FLUIDS; DESIGN; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

IONS;

3,4 METHYLENEDIOXYAMPHETAMINE; PIPERAZINE;

ACCURACY; ARTICLE; DRUG SCREENING; DRUG URINE LEVEL; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; NEUTRAL LOSS SCAN; PERCURSOR ION SCAN; PRIORITY JOURNAL; SCINTISCANNING; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

3,4-METHYLENEDIOXYAMPHETAMINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESIGNER DRUGS; HUMANS; IONS; LIMIT OF DETECTION; PIPERAZINES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 84872351385     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.3115     Document Type: Article

References (42)

1. A. Wohlfarth, W. Weinmann,. Bioanalysis of new designer drugs. Bioanalysis 2010, 2, 965-79.
2. F. T. Peters, J. A. Martinez-Ramirez,. Analytical toxicology of emerging drugs of abuse. Ther. Drug Monit. 2010, 32, 532.
3. L. A. King, A. T. Kicman,. A brief history of 'new psychoactive substances'. Drug Test. Anal. 2011, 3, 401.
4. A. Wohlfarth, W. Weinmann, S. Dresen,. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum. Anal. Bioanal. Chem. 2010, 396, 2403.
5. D. de Boer, I. J. Bosman, E. Hidvegi, C. Manzoni, A. A. Benko, L. J. dos Reys, R. A. Maes,. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci. Int. 2001, 121, 47.
6. P. Gee, T. Jerram, D. Bowie,. Multiorgan failure from 1-benzylpiperazine ingestion - legal high or lethal high? Clin. Toxicol. (Phila.) 2010, 48, 230.
7. B. Byrska, D. Zuba, R. Stanaszek,. Determination of piperazine derivatives in "legal highs". Prob. Forensic Sci. 2010, 81, 101.
8. B. M. Z. Cohen, R. Butler,. BZP-party pills: A review of research on benzylpiperazine as a recreational drug. Int. J. Drug Policy 2011, 22, 95.
9. S. Elliott,. Cat and mouse: the analytical toxicology of designer drugs. Bioanalysis 2011, 3, 249.
10. R. F. Staack, G. Fritschi, H. H. Maurer,. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 773, 35.
11. S. P. Vorce, J. M. Holler, B. Levine, M. R. Past,. TECHNICAL NOTE: Detection of 1-Benzylpiperazine and 1-(3-Trifluoromethylphenyl)-piperazine in Urine Analysis Specimens Using GC-MS and LC-;ESI-MS. J. Anal. Toxicol. 2008, 32, 444.
12. U. Antia, M. D. Tingle, B. R. Russell,. Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J. Forensic Sci. 2010, 55, 1311.
13. H. Tsutsumi, M. Katagi, A. Miki, N. Shima, T. Kamata, M. Nishikawa, K. Nakajima, H. Tsuchihashi,. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 819, 315.
14. S. Pichini, M. Pujadas, E. Marchei, M. Pellegrini, J. Fiz, R. Pacifici, P. Zuccaro, M. Farre, R. de la Torre,. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers. J. Pharm. Biomed. Anal. 2008, 47, 335.
15. T. Kraemer, H. H. Maurer,. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther. Drug Monit. 2002, 24, 277.
16. M. Concheiro, S. M. D. Simões, Ó. Quintela, A. de Castro, M. J. R. Dias, A. Cruz, M. Lõpez-Rivadulla,. Fast LC-MS/MS method for the determination of amphetamine, methamphetamine, MDA, MDMA, MDEA, MBDB and PMA in urine. Forensic Sci. Int. 2007, 171, 44.
17. M. Chèze, M. Deveaux, C. Martin, M. Lhermitte, G. Pépin,. Simultaneous analysis of six amphetamines and analogues in hair, blood and urine by LC-ESI-MS/MS: Application to the determination of MDMA after low Ecstasy intake. Forensic Sci. Int. 2007, 170, 100.
18. H. H. Maurer,. in Handbook of Analytical Separations, M. J. Bogusz, (Ed). Elsevier Science B.V.: Amsterdam, 2007, 425-445.
19. R. F. Staack, H. H. Maurer,. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 798, 333.
20. R. F. Staack, H. H. Maurer,. New designer drug 1-(3,4- methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2004, 39, 255.
21. R. F. Staack, G. Fritschi, H. H. Maurer,. New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J. Mass Spectrom. 2003, 38, 971.
22. M. R. Meyer, J. Wilhelm, F. T. Peters, H. H. Maurer,. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 2010, 397, 1225.
23. F. T. Peters, S. Schaefer, R. F. Staack, T. Kraemer, H. H. Maurer,. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J. Mass Spectrom. 2003, 38, 659.
24. S. Broecker, S. Herre, B. Wüst, J. Zweigenbaum, F. Pragst,. Development and practical application of a library of CID accurate mass spectra of more than 2,500 toxic compounds for systematic toxicological analysis by LC-QTOF-MS with data-dependent acquisition. Anal. Bioanal. Chem. 2011, 400, 101.
25. T. N. Decaestecker, S. R. Vande Casteele, P. E. Wallemacq, C. H. Van Peteghem, D. L. Defore, J. F. Van Bocxlaer. Information-Dependent Acquisition-Mediated LC-MS/MS Screening Procedure with Semiquantitative Potential. Anal. Chem. 2004, 76, 6365.
26. A. Triolo, M. Altamura, T. Dimoulas, A. Guidi, A. Lecci, M. Tramontana,. In vivo metabolite detection and identification in drug discovery via LC-MS/MS with data-dependent scanning and postacquisition data mining. J. Mass Spectrom. 2005, 40, 1572.
27. M. Gergov,. in Handbook of Analytical Separations, M. J. Bogusz, (Ed). Elsevier Science B.V.: Amsterdam, 2007, 491-511.
28. E. B. Jones,. in Mass Spectrometry in Drug Metabolism and Pharmacokinetics, R. Ramanathan, (Ed). John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2008, 123-157.
29. R. J. C. A. Steen, I. Bobeldijk, U. A. T. Brinkman,. Screening for transformation products of pesticides using tandem mass spectrometric scan modes. J. Chromatogr. A 2001, 915, 129-137.
30. S. Kazuno, M. Yanagida, N. Shindo, K. Murayama,. Mass spectrometric identification and quantification of glycosyl flavonoids, including dihydrochalcones with neutral loss scan mode. Anal. Biochem. 2005, 347, 182.
31. H.-H. Hsiao, H. Urlaub,. Pseudo-neutral-loss scan for selective detection of phosphopeptides and N-glycopeptides using liquid chromatography coupled with a hybrid linear ion-trap/orbitrap mass spectrometer. Proteomics 2010, 10, 3916.
32. H. S. Gadgil, P. V. Bondarenko, M. J. Treuheit, D. Ren,. Screening and Sequencing of Glycated Proteins by Neutral Loss Scan LC/MS/MS Method. Anal. Chem. 2007, 79, 5991.
33. D. Compagnone, R. Curini, G. D'Ascenzo, M. Del Carlo, C. Montesano, S. Napoletano, M. Sergi,. Neutral loss and precursor ion scan tandem mass spectrometry for study of activated benzopyrene-DNA adducts. Anal. Bioanal. Chem. 2011, 401, 1983.
34. SOFT, AAFS, Forensic Toxicology Laboratory Guidelines, S. AAFS, Editor. 2006: http://www.soft-tox.org/files/Guidelines-2006-Final.pdf.
35. M. Sergi, D. Compagnone, R. Curini, G. D'Ascenzo, M. Del Carlo, S. Napoletano, R. Risoluti,. Micro-solid phase extraction coupled with high-performance liquid chromatography-tandem mass spectrometry for the determination of stimulants, hallucinogens, ketamine and phencyclidine in oral fluids. Anal. Chim. Acta 2010, 675, 132.
36. B. H. Chen, J. T. Liu, W. X. Chen, H. M. Chen, C. H. Lin,. A general approach to the screening and confirmation of tryptamines and phenethylamines by mass spectral fragmentation. Talanta 2008, 74, 512.
37. L. Bijlsma, J. V. Sancho, F. Hernandez, W. M. A. Niessen,. Fragmentation pathways of drugs of abuse and their metabolites based on QTOF MS/MS and MSE accurate-mass spectra. J. Mass Spectrom. 2011, 46, 865.
38. R. Kikura-Hanajiri, M. Kawamura, A. Miyajima, M. Sunouchi, Y. Goda,. Determination of a new designer drug, N-hydroxy-3,4- methylenedioxymethamphetamine and its metabolites in rats using ultra-performance liquid chromatography-tandem mass spectrometry. Forensic Sci. Int. 2010, 198, 62.
39. L. G. Apollonio, I. R. Whittall, D. J. Pianca, J. M. Kyd, W. A. Maher,. Product ion mass spectra of amphetamine-type substances, designer analogues, and ketamine using ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 2259.
40. M. D. Arbo, M. L. Bastos, H. F. Carmo,. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 2012, 122, 174.
41. T. T. Abraham, A. J. Barnes, R. H. Lowe, E. A. Kolbrich Spargo, G. Milman, S. O. Pirnay, D. A. Gorelick, R. S. Goodwin, M. A. Huestis,. Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. J. Anal. Toxicol. 2009, 33, 439.
42. F. T. Peters, O. H. Drummer, F. Musshoff,. Validation of new methods. Forensic Sci. Int. 2007, 165, 216.